Targeting brain inflammation by either prevention (such as avoidance of traumatic brain injury, addressing vascular risk factors, greater ω-3 dietary consumption), or by targeting the enzymes that activate lipid inflammation pathways (such as cPLA2) are promising strategies to reverse the progression of disease in APOE4 carriers with or at risk of dementia. The gene discussed is PLA2G4A; the disease is dementia.